Table 2.

Maximal lytic capacity of un-/modified IgA Abs in human PMN ADCC assay.

	top plateau; 95% CI [lower-higher]
	without albumin	with albumin
IgA1	49% [45–54%]	47% [44–50%]
IgA1-LCABD	57% [54–60%]	52% [49–54%]
IgA1-HCABD	51% [49–53%]	23% [21–24%]
IgA2	44% [41–47%]	46% [43–50%]
IgA2-LCABD	40% [34–40%]	36% [34–38%]
IgA2-HCABD	38% [34–42%]	16% [14–18%]